Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

The latest example of this trend is Merck KGaA’s impending all-cash acquisition of SpringWorks Therapeutics, valued around ...

Robi, 30, was vaccinated with Gardasil as a teenager and claims the shot led to impaired mobility that confined her to a ...

Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the ...

(Reuters) - Merck and a woman suing the drugmaker agreed to halt a trial over alleged injuries from the drugmaker's human ...

Merck (MRK) and a woman suing the company have agreed to pause a trial over alleged injuries linked to its human papillomavirus vaccine, a case ...

Germany’s Merck KGaA has signed a collaboration with Tencent ... and reforms from the country’s drugs regulator to make it faster at approving new medicines, will drive development of the ...

There’s a new biotech on the scene after MoonLake Immunotherapeutics launched on a mission to develop sonelokimab, a potential inflammatory diseases drug in-licensed from Germany’s Merck KGaA.

thyssenkrupp nucera AG & Co. KGaA (ETR:NCH2) defied analyst predictions to release its first-quarter results, which were ahead of market expectations. thyssenkrupp nucera KGaA delivered a ...

thyssenkrupp nucera AG & Co. KGaA (ETR:NCH2) defied analyst predictions to release its first-quarter results, which were ahead of market expectations. thyssenkrupp nucera KGaA delivered a significant ...